Judges award Niagen for its “high-quality,
unparalleled” healthy aging research
ChromaDex Corp. (NASDAQ:CDXC), the global authority on
nicotinamide adenine dinucleotide (NAD+) and healthy aging
research, is proud to announce that its flagship ingredient,
Niagen® (patented nicotinamide riboside, NR), the most efficient
and high-quality NAD+ booster and the active ingredient in the
company’s consumer supplement, Tru Niagen®, has been awarded the
NutraIngredients EU Healthy Ageing Ingredient of the Year Award.
This recognition underscores the significant contributions Niagen
has made to the field of healthy aging and its role in supporting
cellular health and healthspan.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240522381230/en/
Niagen awarded the 2024 NutraIngredients
EU Healthy Ageing Ingredient of the Year Award (Graphic: Business
Wire)
Recognized globally as a benchmark for excellence, the
NutraIngredients EU Awards celebrate the best innovations and
cutting-edge research in the nutraceutical industry. The Healthy
Ageing Ingredient of the Year Award showcases “the best the
industry has to offer in tailored solutions to support consumers to
remain physically and mentally healthy as they age.” On page 10 of
the Award Winners’ Brochure, a panel of judges noted, “Niagen was
chosen as a winner for its high-quality, unparalleled research. The
judges thought its impact on cellular health and longevity is shown
in reputable studies and is an applicable ingredient for the
Millennial, Generation X, and Baby Boomer generations.”
“On behalf of the ChromaDex team, we are honored to receive this
award for our ingredient, Niagen. We believe Niagen can extend
healthspan, the amount of time we live healthy lives,” remarked Rob
Fried, CEO of ChromaDex and Founder of Tru Niagen. “Our mission at
Chromadex is to help solve the problem of aging through NAD
augmentation and we are committed to the highest scientific and
quality standards. Thank you NutraIngredients for this
recognition.”
NAD+ is an essential coenzyme that plays a vital role in
cellular functions, including mitochondrial function, cellular
energy production, and DNA repair. Research has shown that
reversing NAD+ depletion has positive effects on inflammation, and
many common age-related health conditions such as Parkinson’s
disease, heart failure, chronic kidney disease, and autoimmune
diseases, among others.
Niagen, the most efficient NAD+ precursor, is backed by two
Nobel Prize winners, 30+ human clinical studies, 300+ published
scientific studies, and has been accepted by the world’s most
rigorous regulatory bodies. This Award highlights ChromaDex's
dedication to pioneering NAD+ research and its commitment to
providing high-quality, science-backed products.
For additional information on the science supporting Niagen
visit www.chromadex.com.
Forward Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to NutraIngredients EU
awarding Niagen for its high-quality, unparalleled research.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. Risks that contribute to the uncertain nature of these
forward-looking statements include the impact of the COVID-19
pandemic on our business and the global economy; our history of
operating losses and need to obtain additional financing; the
growth and profitability of our product sales; our ability to
maintain sales, marketing and distribution capabilities; changing
consumer perceptions of our products; our reliance on a single or
limited number of third-party suppliers; and the risks and
uncertainties associated with our business and financial condition.
More detailed information about ChromaDex and the risk factors that
may affect the realization of forward-looking statements is set
forth in ChromaDex's Annual Report on Form 10-K for the fiscal year
ended December 31, 2023, ChromaDex's Quarterly Reports on Form 10-Q
and other filings submitted by ChromaDex to the SEC, copies of
which may be obtained from the SEC's website at www.sec.gov.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and actual results may differ materially from those suggested by
these forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
About ChromaDex:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on
nicotinamide adenine dinucleotide (NAD+), with a focus on the
science of healthy aging. The ChromaDex team, comprised of
world-renowned scientists, works with independent investigators
from esteemed universities and research institutions around the
globe to uncover the full potential of NAD+. A vital coenzyme found
in every cell of the human body, NAD+ declines with age and
exposure to other everyday stressors. NAD+ depletion is a
contributor to age-related changes in health and vitality. Setting
the benchmark as the gold standard in scientific rigor, safety,
quality, and transparency, ChromaDex is the innovator behind its
clinically proven flagship ingredient, Niagen® (patented
nicotinamide riboside, or NR), the most efficient and
superior-quality NAD+ booster available.
Niagen NR is the active ingredient in ChromaDex’s consumer
products, sold as the brand Tru Niagen®, the number one
healthy-aging NAD+ supplement in the United States†. Clinically
proven to increase NAD+ levels, Tru Niagen is helping people around
the world transform the way they age (available at
www.truniagen.com). ChromaDex’s robust patent portfolio protects NR
and other NAD+ precursors. ChromaDex maintains a website at
www.chromadex.com, to which ChromaDex regularly publishes copies of
its press releases, news, and financial information.
†Based on the top-selling dietary supplement brands by revenue
per the largest U.S. e-commerce marketplace (as of
3/1/2023-2/29/2024).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522381230/en/
ChromaDex Media: Kendall Knysch, Senior Director of Media
Relations & Partnerships 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations: Ben Shamsian Lytham
Partners 646-829-9701 shamsian@lythampartners.com
ChromaDex (NASDAQ:CDXC)
過去 株価チャート
から 5 2024 まで 6 2024
ChromaDex (NASDAQ:CDXC)
過去 株価チャート
から 6 2023 まで 6 2024